Mostrar el registro sencillo del ítem

dc.contributor.author
Barcudi, Danilo Andres  
dc.contributor.author
Blasko, Enrique Gabriel  
dc.contributor.author
Gonzalez, María José  
dc.contributor.author
Gagetti, Paula Silvana  
dc.contributor.author
Lamberghini, Ricardo  
dc.contributor.author
Garnero, Analía  
dc.contributor.author
Sarkis, Claudia  
dc.contributor.author
Faccone, Diego Francisco  
dc.contributor.author
Lucero, Celeste  
dc.contributor.author
Tosoroni, Dario  
dc.contributor.author
Bocco, Jose Luis  
dc.contributor.author
Corso, Alejandra  
dc.contributor.author
Sola, Claudia del Valle  
dc.date.available
2023-12-15T13:16:18Z  
dc.date.issued
2023-11  
dc.identifier.citation
Barcudi, Danilo Andres; Blasko, Enrique Gabriel; Gonzalez, María José; Gagetti, Paula Silvana; Lamberghini, Ricardo; et al.; Different evolution of S. aureus methicillin-resistant and methicillin-susceptible infections, Argentina; Elsevier; Heliyon; 11-2023; 1-53  
dc.identifier.issn
2405-8440  
dc.identifier.uri
http://hdl.handle.net/11336/220401  
dc.description.abstract
Staphylococcus aureus-(SA) is widespread among healthcare-associated-(HA) and the community-associated-(CA) infections. However, the contributions of MRSA and MSSA to the SA overall burden remain unclear. In a nationally-representative-survey conducted in Argentina, 668 SA clinical isolates from 60 hospitals were examined in a prospective, cross-sectional, multicenter study in April 2015. The study aimed to analyze MRSA molecular epidemiology, estimate overall SA infection incidence (MSSA, MRSA, and genotypes) in community-onset (CO: HACO, Healthcare Associated-CO and CACO, Community-Associated-CO) and healthcare-onset (HO: HAHO, Healthcare-associated-HO) infections, stratified by age groups. Additionally temporal evolution was estimated by comparing this study´s (2015) incidence values with a previous study (2009) in the same region. Erythromycin-resistant-MSSA and all MRSA strains were genetically typed. The SA total-infections (TI) overall-incidence was 49.1/100,000 monthly-visits, 25.1 and 24.0 for MRSA and MSSA respectively (P=0.5889), in April 2015. In adults with invasive infections (INVI), MSSA was 15.7 and MRSA was 11.8 (P=0.0288), 1.3-fold higher. HA SA infections, both MSSA and MRSA, surpassed CA infections by over threefold. During 2009-2015, there was a significant 23.4% increase in the SA infections overall incidence, mainly driven by MSSA, notably a 54.2% increase in INVI among adults, while MRSA infection rates remained stable. The MSSA rise was accompanied by increased antimicrobial resistance, particularly to erythromycin, linked to MSSA-CC398-t1451-ermT + - IEC+ -pvl- emergence. The SA-infections rise was primarily attributed to community-onset infections (37.3% and 62.4% increase for TI and INVI, respectively), particularly HACO MSSA and HACO-MRSA in adults, as well as CACO-MSSA. The main CA-MRSA-PFGEtypeN-ST30-SCCmecIVc-PVL+/- clone along with other clones (USA300-ST8-IV-LV-PVL+/- , Journal Pre-proof 5 PFGE-typeDD-ST97-IV- PVL- ) added to rather than replaced CA-MRSA-PFGE-typeI-ST5- SCCmecIVa-PVL+/- clone in HA invasive-infections. They also displaced clone HA-MRSA PFGE-typeA-ST5-SCCmecI, mainly in HAHO infections The overall-burden of SA infections is rising in Argentina, driven primarily by community onset MSSA, particularly in adults, linked to increased erythromycin-resistance and MSSACC398-t1451-ermT + -IEC+ -pvl- emergence. Novel knowledge and transmission-control strategies are required for MSSA  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Elsevier  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
STAPHYLOCOCCUS AUREUS  
dc.subject
MRSA  
dc.subject
METHICILLIN-RESISTANCE  
dc.subject
EVOLUTION  
dc.subject.classification
Epidemiología  
dc.subject.classification
Ciencias de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Different evolution of S. aureus methicillin-resistant and methicillin-susceptible infections, Argentina  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-12-14T12:46:34Z  
dc.journal.pagination
1-53  
dc.journal.pais
Reino Unido  
dc.description.fil
Fil: Barcudi, Danilo Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.description.fil
Fil: Blasko, Enrique Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.description.fil
Fil: Gonzalez, María José. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.description.fil
Fil: Gagetti, Paula Silvana. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina  
dc.description.fil
Fil: Lamberghini, Ricardo. Universidad Nacional de Córdoba; Argentina  
dc.description.fil
Fil: Garnero, Analía. Gobierno de la Provincia de Cordoba. Ministerio de Salud. Hospital de Niños de la Santísima Trinidad.; Argentina  
dc.description.fil
Fil: Sarkis, Claudia. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina  
dc.description.fil
Fil: Faccone, Diego Francisco. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Lucero, Celeste. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina  
dc.description.fil
Fil: Tosoroni, Dario. Universidad Nacional de Córdoba; Argentina  
dc.description.fil
Fil: Bocco, Jose Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.description.fil
Fil: Corso, Alejandra. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas. Área de Antimicrobianos; Argentina  
dc.description.fil
Fil: Sola, Claudia del Valle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina  
dc.journal.title
Heliyon  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2405844023098183  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.heliyon.2023.e22610